Organization | Provepharm Sas

Provepharm Sas Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4

Founded: Marseilles France (1998)

Organization Overview

First Clinical Trial

2018

NCT03395223

First Marketed Drug

1998

dimercaprol

First NDA Approval

2016

methylene blue (proveblue)

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Prove pharm | Provepharm Life Solutions | Provepharm SAS | PROVEPHARM SAS

Active Ingredients

Marketed Drugs (8)

dihydroergotamine (D.H.E. 45) (2020)

dimercaprol (1946)

indigotindisulfonate sodium (Bludigo) (2022 NDA)

methylene blue (proveblue) (2016 NDA)

phenylephrine (Prefrin) (2020)

piperacillin (pipracil) (2017)

tazobactam (Zosyn) (2017)

tranexamic acid (cyklokapron) (2019)

Drugs in Phase 4 Trials (3)

indigotindisulfonate sodium (Bludigo) (2 trials)

methylene blue (proveblue) (2 trials)

sodium chloride (2 trials)

Drugs in Phase 3 Trials (1)

indigo (1 trial)

Drugs in Phase 2 Trials (1)

phenylephrine (Prefrin) (1 trial)

Indications

Approved Indications

Methemoglobinemia

Skin Diseases, Infectious

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)

Methemoglobinemia (Phase 4)

Shock (Phase 2)

Shock, Septic (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 5